美參議院委員會通過生物安全法案 藥明康德(02359.HK)挫16%
美國參議院國土安全委員會通過一項可能限制與華大基因(BGI)及藥明康德(02359.HK)等中國生物科技公司在美國開展業務的法案,該法案旨在防止外國競爭對手獲取美國人的個人健康及遺傳基因資料。
藥明康德今日(7日)現報47.6元,跌15.98%,成交90.32萬股,涉資4,309.86萬元。藥明生物(02269.HK)現報18.4元,跌15.4%,成交556.11萬股,涉資1.01億元。
今次委員會是以11比1通過法案,該法案必須在參議院及眾議院全體會議上獲得通過,然後獲總統拜登簽署,目前尚不清楚該法案何時將提交至參議院投票。
藥明康德發聲明稱,公司不收集基因數據,該法案依靠誤導性指控及不準確的訊息,在未經正當程序的情況下對公司提出先發制人及不合理的禁令。華大基因則稱,公司無法存取美國人的個人資料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.